Clinical Trials.gov. Testing the effectiveness of an anti-cancer drug, triapine, when used with targeted radiation-based treatment (lutetium Lu 177 dotatate), compared to lutetium Lu 177 dotatate alone for metastatic neuroendocrine tumors. Updated May 13, 2026. Accessed June 12, 2026. https://clinicaltrials.gov/study/NCT05724108

Corbett V, Gupta G, Chauhan A. PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Endocr Relat Cancer. 2026;33(3):e250495. doi:10.1530/ERC-25-0495

Deshayes E, Assenat E, Meignant L, Bardiès M, Santoro L, Gourgou S. A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH). BMC Cancer. 2022;22(1):1346. doi:10.1186/s12885-022-10443-4

Guillaume N, Chirindel A, Kaul F, et al. [⁶¹Cu]Cu-NODAGA-LM3 versus [⁶⁸Ga]Ga-DOTATOC in the same patients with neuroendocrine tumors: results of the phase I/II COPPER-PET-in-NET trial [abstract 261595] [session: SS15: Neuroendocrine oncology—clinical diagnosis and therapy]. Abstract presented at: 2026 Society of Nuclear Medicine & Molecular Imaging Annual Meeting; May 30-June 2, 2026; Los Angeles, CA.

Hardiansyah D, Kaiser L, Costa PF, et al. Accurate single-time-point dosimetry of [177Lu]Lu-edotreotide using non-linear mixed-effects modeling: results from the COMPETE phase 3 trial [abstract 261100] [session: Science pavilion]. Poster presented at: 2026 Society of Nuclear Medicine & Molecular Imaging Annual Meeting; May 30-June 2, 2026; Los Angeles, CA.

Nicolas GP, Lafont MA, McDougall L, et al. First-in-human administration of [⁶¹Cu]Cu-NODAGA-LM3 and head-to-head comparison with [⁶⁸Ga]Ga-DOTA-TOC PET/CT as part of the phase I/II COPPER PET in NET study. Eur J Nucl Med Mol Imaging. 2026;53(2):710-712. doi:10.1007/s00259-025-07301-3

Perrone E, Ghai K, Eismant A, et al. Beyond β-peptide receptor radionuclide therapy (PRRT) with somatostatin receptor (SSTR) agonists: real-world outcomes of SSTR antagonist α-PRRT in heavily pretreated G3 neuroendocrine neoplasms [abstract 261577] [session: SS15: Neuroendocrine oncology—clinical diagnosis and therapy]. Abstract presented at: 2026 Society of Nuclear Medicine & Molecular Imaging Annual Meeting; May 30-June 2, 2026; Los Angeles, CA.

Sgouros G, Ulaner GA, He B, et al. Dosimetry results from the phase 1b/3 ACTION-1 trial of [²²⁵AC]Ac-DOTATATE (RYZ101) in patients with somatostatin receptor-expressing, well-differentiated GEP-NETs. J Nucl Med. Published online June 4, 2026. doi:10.2967/jnumed.125.270573

Sgouros G, Ulaner G, Delie T, et al. 225Ac-DOTATATE dosimetry results from part 1 of the ACTION-1 trial. J Nucl Med. 2023;64(suppl 1):P129.

This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the Society of Nuclear Medicine & Molecular Imaging.